[Description]:
Palonosetron-d3 hydrochloride is the deuterium labeled Palonosetron hydrochloride. Palonosetron hydrochloride is a 5-HT3 antagonist used in the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV)[1][2].
[Related Catalog]:
[In Vitro]
Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
[References]
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.
[2]. Vishnu Murthy M, Srinivas K, Kumar R, Mukkanti K.Development and validation of a stability-indicating LC method for determining palonosetron hydrochloride, its related compounds and degradation products using naphthalethyl stationary phase.J Pharm Biomed Anal. 2011 Sep 10;56(2):429-35.
[3]. Ajioka H, Morita F, Akizawa Y, Yoshida K, Kitamura R, Takimoto H.Pharmacological, pharmacokinetic, and clinical profile of palonosetron hydrochloride (ALOXI I.V. Injection 0.75 mg), a novel antiemetic 5-HT3-receptor antagonist.Nihon Yakurigaku Zasshi. 2010 Aug;136(2):113-20.
[4]. Ruhlmann C, Herrstedt J.Palonosetron hydrochloride for the prevention of chemotherapy-induced nausea and vomiting.Expert Rev Anticancer Ther. 2010 Feb;10(2):137-48.
[5]. Trissel LA, Trusley C, Ben M, Kupiec TC.Physical and chemical stability of palonosetron hydrochloride with five opiate agonists during simulated Y-site administration.Am J Health Syst Pharm. 2007 Jun 1;64(11):1209-13.
[6]. Clark, Robin D.; Miller, Aaron B.; Berger, Jacob; Repke, David B.; Weinhardt, Klaus K.; Kowalczyk, Bruce A.; Eglen, Richard M.; Bonhaus, Douglas W.; Lee, Chi Ho; et al.2-(Quinuclidin-3-yl)pyrido[4,3-b]indol-1-ones and isoquinolin-1-ones. Potent conformationally restricted 5-HT3 receptor antagonists.J. Med. Chem., 1993, 36 (18), pp 2645-2657